Efficacy of Imatinib on Advanced and Refractory Desmoid Tumors: A Retrospective Study
Received Date : 03 Dec 2021
Accepted Date : 22 Apr 2022
Available Online : 12 May 2022
Doi: 10.37047/jos.2021-87391 - Article's Language: EN
J Oncol Sci. 2022;8(2):63-8
This is an open access article under the CC BY-NC-ND license
Objective: Our study aimed to analyze imatinib’s efficacy, tolerability, and safety in treating naive patients with unresectable and progressive desmoid tumors. Material and Methods: The data of patients who were ≥18 years old diagnosed with desmoid tumors treated with imatinib were evaluated retrospectively regarding their demographic features, comorbidities, disease stage, pathological features of the tumor, and response rates and progression-free survival (PFS). Results: In our study, 36 patients with advanced desmoid tumors receiving imatinib with a median age of 28 [interquartile range (IQR): 21-40] of whom 58.3% were female were included. The patient’s complete response, partial response, stable disease, and progressive disease with imatinib 800 mg/day were 13.9%, 44.4%, 27.7%, and 13.9%, respectively. The Grade-3 adverse events, including neutropenia (n=3, 8.3%) and rash (n=3, 8.3%), were relieved after dose reduction. The median PFS was 29 months (95% confidence interval, 16-42 months) with imatinib, and only 3 (8.3%) patients were exitus due to disease progression during the follow-up (median: 43 months, IQR: 24.3-70.8). Conclusion: Our study provided clinical evidence of the efficacy and safety of imatinib in patients with desmoid tumors with real-world experience. However, appropriately designed randomized-controlled clinical trials are needed to explore the effectiveness of imatinib in desmoid tumors to provide an alternative management approach.
  1. Dufresne A, Bertucci F, Penel N, et al. Identification of biological factors predictive of response to imatinib mesylate in aggressive fibromatosis. Br J Cancer. 2010;103(4):482-485. [Crossref]  [PubMed]  [PMC] 
  2. Penel N, Chibon F, Salas S. Adult desmoid tumors: biology, management and ongoing trials. Curr Opin Oncol. 2017;29(4):268-274. [Crossref]  [PubMed]  [PMC] 
  3. Smith K, Desai J, Lazarakis S, Gyorki D. Systematic review of clinical outcomes following various treatment options for patients with extraabdominal desmoid tumors. Ann Surg Oncol. 2018;25(6):1544-1554. [Crossref]  [PubMed] 
  4. Nieuwenhuis MH, Casparie M, Mathus-Vliegen LM, Dekkers OM, Hogendoorn PC, Vasen HF. A nation-wide study comparing sporadic and familial adenomatous polyposis-related desmoid-type fibromatoses. Int J Cancer. 2011;129(1):256-261. [Crossref]  [PubMed] 
  5. Fallen T, Wilson M, Morlan B, Lindor NM. Desmoid tumors--a characterization of patients seen at Mayo Clinic 1976-1999. Fam Cancer. 2006;5(2):191-194. [Crossref]  [PubMed] 
  6. Koskenvuo L, Peltomäki P, Renkonen-Sinisalo L, et al. Desmoid tumor patients carry an elevated risk of familial adenomatous polyposis. J Surg Oncol. 2016;113(2):209-212. [Crossref]  [PubMed] 
  7. Kasper B, Baumgarten C, Garcia J, et al; Desmoid Working Group. An update on the management of sporadic desmoid-type fibromatosis: a European Consensus Initiative between Sarcoma PAtients EuroNet (SPAEN) and European Organization for Research and Treatment of Cancer (EORTC)/Soft Tissue and Bone Sarcoma Group (STBSG). Ann Oncol. 2017;28(10):2399-2408. [Crossref]  [PubMed]  [PMC] 
  8. Turner B, Alghamdi M, Henning JW, et al. Surgical excision versus observation as initial management of desmoid tumors: a population based study. Eur J Surg Oncol. 2019;45(4):699-703. [Crossref]  [PubMed] 
  9. DE Marchis ML, Tonelli F, Quaresmini D, et al. Desmoid tumors in familial adenomatous polyposis. Anticancer Res. 2017;37(7):3357-3366. [Crossref]  [PubMed] 
  10. Timbergen MJM, Schut AW, Grünhagen DJ, Sleijfer S, Verhoef C. Active surveillance in desmoid-type fibromatosis: a systematic literature review. Eur J Cancer. Sep 2020;137:18-29. [Crossref]  [PubMed] 
  11. Kasper B, Baumgarten C, Bonvalot S, et al; Desmoid Working Group. Management of sporadic desmoid-type fibromatosis: a European consensus approach based on patients' and professionals' expertise-a sarcoma patients EuroNet and European Organisation for Research and Treatment of Cancer/Soft Tissue and Bone Sarcoma Group initiative. Eur J Cancer. 2015;51(2):127-136. [Crossref]  [PubMed] 
  12. Wilding CP, Elms ML, Judson I, Tan AC, Jones RL, Huang PH. The landscape of tyrosine kinase inhibitors in sarcomas: looking beyond pazopanib. Expert Rev Anticancer Ther. 2019;19(11):971-991. [Crossref]  [PubMed]  [PMC] 
  13. Mazzocca A, Napolitano A, Silletta M, et al. New frontiers in the medical management of gastrointestinal stromal tumours. Ther Adv Med Oncol. May 2019;11:1758835919841946. [Crossref]  [PubMed]  [PMC] 
  14. Mace J, Sybil Biermann J, Sondak V, et al. Response of extraab dominal desmoid tumors to therapy with imatinib mesylate. Cancer. 2002;95(11):2373-2379. [Crossref]  [PubMed] 
  15. Dufresne A, Alberti L, Brahmi M, et al. Impact of KIT exon 10 M541L allelic variant on the response to imatinib in aggressive fibromatosis: analysis of the desminib series by competitive allele specific Taqman PCR technology. BMC Cancer. Aug 2014;14:632. [Crossref]  [PubMed]  [PMC] 
  16. Maekawa T, Ashihara E, Kimura S. The Bcr-Abl tyrosine kinase inhibitor imatinib and promising new agents against Philadelphia chromosome-positive leukemias. Int J Clin Oncol. 2007;12(5):327-340. [Crossref]  [PubMed] 
  17. Cates JMM. The AJCC 8th edition staging system for soft tissue sarcoma of the extremities or trunk: a cohort study of the SEER database. J Natl Compr Canc Netw. 2018;16(2):144-152. [Crossref]  [PubMed] 
  18. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000;92(3):205-216. [Crossref]  [PubMed] 
  19. Kasper B, Gruenwald V, Reichardt P, et al. Imatinib induces sustained progression arrest in RECIST progressive desmoid tumours: final results of a phase II study of the German Interdisciplinary Sarcoma Group (GISG). Eur J Cancer. May 2017;76:60-67. [Crossref]  [PubMed] 
  20. Basch E, Reeve BB, Mitchell SA, et al. Development of the National Cancer Institute's patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE). J Natl Cancer Inst. 2014;106(9):dju244. [Crossref]  [PubMed]  [PMC] 
  21. Fletcher CDM, Bridge JA, Hogendoorn PCW, Mertens F. WHO Classification Soft Tissue and Bone Tumors. Goldblum JR, Fletcher JA, Desmoid-type fibromatosis 4th edition. Lyon: IARC Press; 2013:72-74.
  22. Gronchi A, Jones RL. Treatment of desmoid tumors in 2019. JAMA Oncol. 2019;5(4):567-568. [Crossref]  [PubMed] 
  23. Quast DR, Schneider R, Burdzik E, Hoppe S, Möslein G. Long-term outcome of sporadic and FAP-associated desmoid tumors treated with high-dose selective estrogen receptor modulators and sulindac: a single-center long-term observational study in 134 patients. Fam Cancer. 2016;15(1):31-40. [Crossref]  [PubMed] 
  24. Heinrich MC, McArthur GA, Demetri GD, et al. Clinical and molecular studies of the effect of imatinib on advanced aggressive fibromatosis (desmoid tumor). J Clin Oncol. 2006;24(7):1195-203. [Crossref]  [PubMed] 
  25. Négrier S, Raymond E. Antiangiogenic treatments and mechanisms of action in renal cell carcinoma. Invest New Drugs. 2012;30(4):1791-1801. [Crossref]  [PubMed] 
  26. Savage DG, Antman KH. Imatinib mesylate--a new oral targeted therapy. N Engl J Med. 2002;346(9):683-693. [Crossref]  [PubMed] 
  27. Mankin HJ, Hornicek FJ, Springfield DS. Extra-abdominal desmoid tumors: a report of 234 cases. J Surg Oncol. 2010;102(5):380-384. [Crossref]  [PubMed] 
  28. Chugh R, Wathen JK, Patel SR, et al; Sarcoma Alliance for Research through Collaboration (SARC). Efficacy of imatinib in aggressive fibromatosis: Results of a phase II multicenter Sarcoma Alliance for Research through Collaboration (SARC) trial. Clin Cancer Res. 2010;16(19):4884-4891. [Crossref]  [PubMed] 
  29. Penel N, Le Cesne A, Bui BN, et al. Imatinib for progressive and recurrent aggressive fibromatosis (desmoid tumors): an FNCLCC/French Sarcoma Group phase II trial with a long-term follow-up. Ann Oncol. 2011;22(2):452-457. [Crossref]  [PubMed] 
  30. Reichardt P, Schlemmer M, Delgado Perez JR, et al. Safety of imatinib mesylate in a multicenter expanded access program in adult patients with gastrointestinal stromal tumors in the adjuvant setting. Oncol Res Treat. 2019;42(12):629-635. [Crossref]  [PubMed]